RCM
AKBA icon

RB Capital Management’s Akebia Therapeutics AKBA Stock Holding History

RB Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$19K – 179
2024
Q4 		$19K Hold
10,000
– – ﹤0.01% 188
2024
Q3 		$13.2K Hold
10,000
– – ﹤0.01% 185
2024
Q2 		$10.2K Hold
10,000
– – ﹤0.01% 177
2024
Q1 		$18.3K Hold
10,000
– – ﹤0.01% 180
2023
Q4 		$12.4K Hold
10,000
– – ﹤0.01% 175
2023
Q3 		$11.4K Hold
10,000
– – ﹤0.01% 170
2023
Q2 		$9.15K Buy
+10,000
New +$9.65K ﹤0.01% 176

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RB Capital Management's AKBA Position: Q1 2025 in Review

RB Capital Management sold out of Akebia Therapeutics (AKBA) in Q1 2025, closing a stake of 10,000 shares — an estimated $19K sold.

RB Capital Management first reported a position in AKBA in Q2 2023 and held it in 7 quarters. The position peaked at $19K in Q4 2024. 143 funds tracked by Wall St. Rank hold AKBA as of Q1 2025.

  • RB Capital Management reported no remaining Akebia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • RB Capital Management sold 10,000 Akebia Therapeutics shares in Q1 2025, an estimated $19K.
  • RB Capital Management first reported a position in Akebia Therapeutics in Q2 2023 and held it in 7 quarters.
  • RB Capital Management's Akebia Therapeutics position peaked at $19K in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2025.

Based on RB Capital Management's 13F filing for Q1 2025, filed 14 May 2025.